Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020-02-01
|
| coleção: | Translational Oncology |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S1936523319304486 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|